Date | Price Target | Rating | Analyst |
---|---|---|---|
8/21/2024 | $92.00 → $94.00 | Perform | Oppenheimer |
8/15/2024 | $76.00 → $90.00 | Sell → Neutral | UBS |
8/14/2024 | $100.00 → $85.00 | Buy → Hold | Stifel |
5/30/2024 | $83.00 | Sell | Goldman |
7/19/2023 | $90.00 | Neutral | Robert W. Baird |
6/30/2023 | $106.00 | Buy | CL King |
5/30/2023 | $104.00 | Equal-Weight → Overweight | Morgan Stanley |
4/24/2023 | $77.00 → $100.00 | Equal Weight → Overweight | Wells Fargo |
Oppenheimer reiterated coverage of Medtronic with a rating of Perform and set a new price target of $94.00 from $92.00 previously
UBS upgraded Medtronic from Sell to Neutral and set a new price target of $90.00 from $76.00 previously
Stifel downgraded Medtronic from Buy to Hold and set a new price target of $85.00 from $100.00 previously
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SC 13G/A - Medtronic plc (0001613103) (Subject)
SAN DIEGO, June 20, 2024 /PRNewswire/ -- Sempra (NYSE:SRE) (BMV:SRE) today announced the appointment of Jennifer M. Kirk to the company's board of directors effective June 20, 2024. Kirk is currently the global controller and chief accounting officer of Medtronic plc (NYSE:MDT) and has deep executive experience in finance, accounting and capital market activities, including more than 20 years in the energy industry. "Bringing new perspectives into the boardroom is a critical component of our effort to support the company's mission to build North America's premier energy infras
NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol
DUBLIN, June 26, 2023 /PRNewswire/ -- Medtronic announced today that its Board of Directors appointed Greg Lewis, Senior Vice President and Chief Financial Officer at Honeywell, to the Board. Lewis will serve on the Audit Committee and the Finance and Financial Risk Committee, effective June 26, 2023. "We are thrilled to have Greg Lewis join our Board. His background in financial leadership across multiple industries will be a strong asset as Medtronic pushes forward a comprehensive transformation that will set us up to deliver on durable growth," said Geoff Martha, Chairman and CEO of Medtronic. "I'm honored to join the Medtronic Board of Directors. I believe in the company's mission to al
GALWAY, Ireland, Aug. 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024. Geoff Martha, Medtronic chairman and chief executive officer, will answer questions on the medtech industry and on the company beginning at approximately 11:55 a.m. EDT (12:55 p.m. CDT). A live webcast of the Q&A session will be available on September 4, 2024, by clicking on the Events link at http://investorrelations.medtronic.com. An archive of the session will be available on the same webpage later in the day. About MedtronicBold thinking. Bolder actions. We are
PaceMate®, a pioneer in cardiac data management and remote monitoring, announced today the acquisition of the Paceart Optima™ system, an on-premises cardiac workflow solution from Medtronic (NYSE:MDT) This strategic move significantly expands PaceMate's reach globally, adding nearly 1,000 clinic locations worldwide. This further enhances PaceMate's ability to provide the leading and most comprehensive cardiac remote monitoring solution, continuing its position as the preferred partner in advanced cardiac data management. "After a comprehensive evaluation, we are confident PaceMate is the best organization to service Paceart customers and their future cardiac data workflow needs," said Kwe
Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain Stimulation GALWAY, Ireland, Aug. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024. Key Highlights Revenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as reported and 5.3% organicGAAP diluted earnings per share (EPS) of $0.80; non-GAAP diluted EPS of $1.23Company increases FY25 organic revenue growth and EPS guidanceMultiple franchises deliv
4 - Medtronic plc (0001613103) (Issuer)
4 - Medtronic plc (0001613103) (Issuer)
3 - Medtronic plc (0001613103) (Issuer)
Abbott Laboratories (NYSE:ABT) CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device. This device targets consumers without diabetes, aiming to personalize health data and enhance understanding of their health metrics. Also Read: Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits. Ford projected that Lingo could become a multi-billion-dollar product, although it is still in its nascent stage. Lingo, an over-the-counter device, is scheduled to launch this year alongside Libre Rio, which received FDA clearance last month. Abbott’s consumer bi
RBC Capital analyst Shagun Singh reiterates Medtronic (NYSE:MDT) with a Sector Perform and maintains $92 price target.
Medtronic (NYSE:MDT) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 5 0 2 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 1 3 0 2 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $88.25, a high estimate of $105.00, and a low estimate of $76.00. This current average represents a 1.79% decrease from the previ
PaceMate®, a pioneer in cardiac data management and remote monitoring, announced today the acquisition of the Paceart Optima™ system, an on-premises cardiac workflow solution from Medtronic (NYSE:MDT) This strategic move significantly expands PaceMate's reach globally, adding nearly 1,000 clinic locations worldwide. This further enhances PaceMate's ability to provide the leading and most comprehensive cardiac remote monitoring solution, continuing its position as the preferred partner in advanced cardiac data management. "After a comprehensive evaluation, we are confident PaceMate is the best organization to service Paceart customers and their future cardiac data workflow needs," said Kwe
Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain Stimulation GALWAY, Ireland, Aug. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024. Key Highlights Revenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as reported and 5.3% organicGAAP diluted earnings per share (EPS) of $0.80; non-GAAP diluted EPS of $1.23Company increases FY25 organic revenue growth and EPS guidanceMultiple franchises deliv
GALWAY, Ireland, Aug. 16, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on October 11, 2024, to shareholders of record at the close of business on September 27, 2024. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, h
IRANNOTICE - Medtronic plc (0001613103) (Filer)
10-Q - Medtronic plc (0001613103) (Filer)
144 - Medtronic plc (0001613103) (Subject)